This is a new service – your feedback will help us to improve it.

About the Fleming Fund


The Fleming Fund is a UK aid programme to help low and middle income countries to fight antimicrobial resistance (AMR).

The Fleming Fund is named after Alexander Fleming who discovered the world's first antibiotic. Fleming's work paved the way for the use of antibiotics in modern healthcare.

When receiving the Nobel Prize in 1945 he warned of a time when antibiotics would become less useful due to frequent or improper use. Fleming, at this time, had predicted AMR.

AMR occurs when microorganisms such as bacteria, viruses, fungi and parasites change in ways that make treatments ineffective. AMR causes drug resistant infections that can kill, spread to others and increase healthcare costs across the world.

AMR is a global issue. Read some important facts about AMR.


“Antimicrobial resistance has the potential to kill millions each year and become a massive burden on health systems across the world. By 2050, if left unchecked, drug-resistant infections will kill 10 million people a year and cost the worldwide economy $100 trillion. To combat this problem, we first need to understand it—and the Fleming Fund is a crucial step in creating a clearer global picture. Having accurate information will make sure the right resources are deployed at the right time, in the right place, to make the maximum impact.”

Chief Medical Officer Professor Dame Sally Davies


The aims of the Fleming Fund

The aim of the Fleming Fund is to get data relevant to AMR in the hands of decision makers.

We want to support countries generating the data they need to inform policies and practices which will optimise the use of antimicrobial medicines.

The Fleming Fund will fund a range of initiatives in low and middle income countries with the aim of increasing the quantity and quality of data available so we can better understand the scale and scope of AMR.

More about the Fleming Fund